221 Users Online
Cyclin-Dependent Kinase (CDK) Inhibitors Market Segmented By type of inhibitor such as Specific inhibitors, Non-specific or broad range inhibitors, Multiple target inhibitors in Nasal, Oral, Intravenous and Intramuscular route of administration
Cyclin-Dependent Kinases (CDK) are protein kinases that play a pivotal role in cell cycle regulation. CDK binds to cyclin to form a complex that functions together. There are about 20 cyclin-dependent kinase (CDK) family members in the human body. Any compound or chemical that inhibits the function of CDKs acts as an inhibitor. Cancer cells over proliferate and to regulate this mechanism Cyclin-Dependent Kinase (CDK) inhibitors are used a treatment.
From last 20 years several CDK inhibitors have been developed as potential cancer targets. The most used first-generation Cyclin-Dependent Kinases (CDK) inhibitor is flavopiridol that has been studied in >60 clinical trials since 1998. There are many Cyclin-Dependent Kinases (CDK) inhibitors in the market amongst which CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 are most used in research and treatment.
Some of the key factor that are driving the growth of the Cyclin-Dependent Kinase (CDK) Inhibitors Market include, rise in R&D spending and activities and increase in oncology research worldwide. The Cyclin-Dependent Kinases (CDK) inhibitors are in extensively in numerous clinical trials making Cyclin-Dependent Kinases (CDK) inhibitor market a most opportunistic field for anticancer treatment.
Increasing cancer prevalence worldwide, increasing incidences of cancer and changing lifestyle tend to drive the growth of Cyclin-Dependent Kinases (CDK) inhibitor market. As reported more than 1.7 million new cases of cancer were seen in 2018 in the US. And the rate of cancer mortality is 163 per 100000 people.
All these factors contribute towards driving the Cyclin-Dependent Kinase (CDK) Inhibitors market. Despite of being a promising drug targets for cancer, almost all the Cyclin-Dependent Kinase (CDK) Inhibitors have failed in clinical trials. This is a major setback for
Most of the non-selective Cyclin-Dependent Kinases (CDK) inhibitors have shown disappointing results seen in the clinical studies. As a result of this, the importance of selectivity of compounds for specific CDKs is gaining attention. Also cost of these inhibitors is higher and cannot be affordable by people in lower and middle economic regions.
|Based on type of inhibitor||
|Based on route of administration||
|Based on target disease||
|Based on distribution channels||
Some of the key players in the market include, Sanofi, Pfizer Inc., Eli Lilly and Company, Novartis, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Merck KGaA, and AstraZeneca and others.